Leukaemia patient shows complete response in Chimeric Therapeutics’ latest trial
Join our daily newsletter At The Bell to receive exclusive market insights Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial – in other words, for now, that patient is cancer-free. …